Published in Mol Psychiatry on February 09, 2010
Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry (2010) 1.70
Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci (2011) 1.48
GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder. Front Mol Neurosci (2012) 1.34
Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28
Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry (2012) 1.05
Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: how important is BDNF? Br J Pharmacol (2014) 0.96
Convergent functional genomic studies of ω-3 fatty acids in stress reactivity, bipolar disorder and alcoholism. Transl Psychiatry (2011) 0.93
Are BDNF and glucocorticoid activities calibrated? Neuroscience (2012) 0.92
The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders. Front Pharmacol (2013) 0.80
Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology (Berl) (2012) 0.79
Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur J Pharmacol (2015) 0.77
Lateral hypothalamic kindling induces manic-like behavior in rats: a novel animal model. Int J Bipolar Disord (2014) 0.77
Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents. Pharmacol Biochem Behav (2011) 0.76
Abnormal development of monoaminergic neurons is implicated in mood fluctuations and bipolar disorder. Neuropsychopharmacology (2014) 0.76
Bipolar disorder: a neurobiological synthesis. Curr Top Behav Neurosci (2011) 0.75
Striatal Transcriptome and Interactome Analysis of Shank3-overexpressing Mice Reveals the Connectivity between Shank3 and mTORC1 Signaling. Front Mol Neurosci (2017) 0.75
Forebrain-specific ablation of phospholipase Cγ1 causes manic-like behavior. Mol Psychiatry (2017) 0.75
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet (2008) 10.49
Whole-genome association study of bipolar disorder. Mol Psychiatry (2008) 6.80
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry (2007) 6.72
Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA (2008) 6.60
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
The many faces of CREB. Trends Neurosci (2005) 5.58
Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A (2007) 3.92
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 3.91
The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov (2005) 3.80
Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (2006) 3.55
The DISC locus in psychiatric illness. Mol Psychiatry (2007) 3.46
Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet (2005) 3.24
Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet (2000) 3.10
Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry (2006) 2.94
Preclinical models: status of basic research in depression. Biol Psychiatry (2002) 2.76
Bipolar disorder. N Engl J Med (2004) 2.75
Behavioral phenotyping strategies for mutant mice. Neuron (2008) 2.74
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A (2007) 2.72
Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry (2007) 2.66
Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet (2003) 2.55
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci (2006) 2.01
Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology (2007) 1.86
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2006) 1.86
Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet (2006) 1.82
The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol (2007) 1.82
The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem (2001) 1.73
Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology (2004) 1.72
Genetics of bipolar disorder: successful start to a long journey. Trends Genet (2009) 1.71
The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) (1988) 1.63
Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry (2006) 1.62
Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry (2009) 1.59
Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc Natl Acad Sci U S A (2004) 1.54
Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet (2003) 1.50
Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci (2007) 1.47
Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol Psychiatry (2004) 1.46
Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci (2007) 1.45
A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. Hum Mol Genet (2001) 1.42
Animal models of mood disorders: Recent developments. Curr Opin Psychiatry (2007) 1.38
Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry (2008) 1.36
Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. Am J Med Genet B Neuropsychiatr Genet (2008) 1.35
Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry (2008) 1.34
Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry (2006) 1.31
BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A (2008) 1.25
The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry (2008) 1.19
The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: the need for earlier and alternative modes of therapeutic intervention. Dev Psychopathol (2006) 1.16
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology (2007) 1.16
From animal models to model animals. Biol Psychiatry (2007) 1.14
A length polymorphism in the circadian clock gene Per3 influences age at onset of bipolar disorder. Neurosci Lett (2008) 1.12
Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology (2006) 1.12
Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry (2000) 1.12
The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev (2007) 1.12
A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett (2004) 1.11
The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci (2005) 1.10
Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport (2005) 1.05
Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett (2004) 1.04
A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett (2004) 1.02
Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol Psychiatry (2006) 1.00
Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit. J Neurosci (2002) 0.98
Genetics of bipolar disorder: focus on BDNF Val66Met polymorphism. Novartis Found Symp (2008) 0.98
The when and where of BDNF and the antidepressant response. Biol Psychiatry (2008) 0.96
BAG-1 family of cochaperones in the modulation of nuclear receptor action. J Steroid Biochem Mol Biol (2001) 0.96
Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord (2008) 0.95
Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate. J Mol Neurosci (2008) 0.95
Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience (2003) 0.95
Genomewide scan and fine-mapping linkage studies in four European samples with bipolar affective disorder suggest a new susceptibility locus on chromosome 1p35-p36 and provides further evidence of loci on chromosome 4q31 and 6q24. Am J Hum Genet (2005) 0.90
Different behaviors and different strains: potential new ways to model bipolar disorder. Neurosci Biobehav Rev (2007) 0.90
Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J Psychiatry Neurosci (2005) 0.86
Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium (2008) 0.86
Altered emotional behaviors and the expression of 5-HT1A and M1 muscarinic receptors in micro-opioid receptor knockout mice. Synapse (2004) 0.86
Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet (2007) 0.86
Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. Eur Neuropsychopharmacol (2006) 0.80
Lithium-induced increase in human brain grey matter. Lancet (2000) 2.31
Enhancement of hippocampal neurogenesis by lithium. J Neurochem (2000) 2.28
The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem (1999) 2.20
The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem (1999) 2.04
Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science (2004) 1.83
The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem (2001) 1.73
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry (2000) 1.55
Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress. Mol Psychiatry (2010) 1.47
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry (2004) 1.39
Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry (2008) 1.36
The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry (2008) 1.19
A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry (2000) 1.06
Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry (1999) 1.05
First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry Suppl (1998) 0.99
The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res (1998) 0.97
Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem (1994) 0.94
Rapid antidepressant effects: moving right along. Mol Psychiatry (2013) 0.93
Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord (2000) 0.92
G proteins and beta ARK: a new twist for the coiled coil. Trends Biochem Sci (1993) 0.89
Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med (1999) 0.89
Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo. J Neurochem (1999) 0.86
The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry (1999) 0.86
Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res (1999) 0.86
Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News Perspect (2003) 0.85
Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain. Biol Psychiatry (1992) 0.85
High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder. Am J Psychiatry (1997) 0.84
Catecholamines in depression: an update. Clin Chem (1994) 0.84
Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem (1998) 0.84
Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry (1999) 0.84
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry (2004) 0.84
Attenuation of cyclic AMP production by carbamazepine. J Neurochem (1996) 0.84
Neurobiology of lithium: an update. J Clin Psychiatry (1998) 0.82
The effects of lithium on ex vivo cytokine production. Biol Psychiatry (2001) 0.81
Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology (1997) 0.81
Lithium stimulates gene expression through the AP-1 transcription factor pathway. Brain Res Mol Brain Res (1998) 0.80
Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf (1994) 0.80
Height, weight and body mass index (BMI) in psychiatrically ill US Armed Forces personnel. Psychol Med (2003) 0.80
Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol Psychiatry (2011) 0.79
The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. Arch Gen Psychiatry (1991) 0.79
Lithium treatment in ovo: effects on embryonic heart rate, natural death of ciliary ganglion neurons, and brain expression of a highly conserved chicken homolog of human MTG8/ETO. Brain Res Dev Brain Res (2000) 0.78
Assessment of bromocriptine intervention for the treatment of frontal lobe syndrome: a case study. J Neuropsychiatry Clin Neurosci (1992) 0.78
Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Res (2000) 0.78
No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder. Arch Gen Psychiatry (1997) 0.78
Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry (1999) 0.78
Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology (1996) 0.77
Down-regulation of PKC alpha by lithium in vitro. Psychopharmacol Bull (1995) 0.77
Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/H+ antiporter activity in HL-60 cells. Eur J Pharmacol (1990) 0.77
Alterations in cyclic AMP generation and G protein subunits following transient ischemia in gerbil hippocampus. J Cereb Blood Flow Metab (1995) 0.76
Lithium administration modulates platelet Gi in humans. Life Sci (1992) 0.76
Bupropion, ECT, and dopaminergic overdrive. Am J Psychiatry (1991) 0.75
ECT and delirium in Parkinson's disease. Am J Psychiatry (1992) 0.75
Lithium revisited: savings brought about by the use of lithium, 1970-1991. Psychiatr Q (2001) 0.75
Commentary on the management of treatment-resistant affective disorder: clinical perspectives. J Psychopharmacol (1992) 0.75
Effect of the 5-HT2 antagonist ketanserin on the ECT-induced prolactin release. Biol Psychiatry (1989) 0.75
Pharmacologic profile of natural products used to treat psychotic illnesses. Psychopharmacol Bull (1995) 0.75
Antidepressants, metabolites, and apparent drug resistance. Clin Neuropharmacol (1990) 0.75
G-protein level quantification in platelets and leukocytes from patients with panic disorder. Neuropsychopharmacology (1996) 0.75
Bromocriptine in neuroleptic resistance. Biol Psychiatry (1987) 0.75
Are monoamine metabolites in cerebrospinal fluid worth measuring? Arch Gen Psychiatry (1993) 0.75
Monoaminergic actions of ECT. Clin Neuropharmacol (1992) 0.75
In vivo evidence that nonneuronal beta-adrenoceptors as well as dopamine receptors contribute to cyclic AMP efflux in rat striatum. J Neurochem (1994) 0.75
Combined measures of noradrenergic output and receptor responsivity in depression. Clin Neuropharmacol (1992) 0.75
Platelet α2-adrenoreceptors in depression: a critical examination. J Psychopharmacol (1993) 0.75